APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

IgA Nephropathy Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global IgA Nephropathy Drugs Market Outlook and Growth Opportunities 2026

Report ID 174001520430 December 2025190 pages

Choose your research edition.

Industry ResearchIgA Nephropathy Drugs Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal IgA Nephropathy Drugs Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal IgA Nephropathy Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal IgA Nephropathy Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal IgA Nephropathy Drugs Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global IgA Nephropathy Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for IgA Nephropathy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for IgA Nephropathy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for IgA Nephropathy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the IgA Nephropathy Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the IgA Nephropathy Drugs market include Calliditas Therapeutics, Chinook Therapeutics, Omeros Corporation, Travere Therapeutics, Vera Therapeutics, Otsuka Pharmaceutical and Novartis International, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global IgA Nephropathy Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of IgA Nephropathy Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents IgA Nephropathy Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the IgA Nephropathy Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

IgA Nephropathy Drugs Segment by Company

Calliditas Therapeutics

Chinook Therapeutics

Omeros Corporation

Travere Therapeutics

Vera Therapeutics

Otsuka Pharmaceutical

Novartis International

IgA Nephropathy Drugs Segment by Type

Phase I

Phase II

Phase III

IgA Nephropathy Drugs Segment by Application

Clinical Treatment

Drug Experiment

IgA Nephropathy Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global IgA Nephropathy Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions IgA Nephropathy Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify IgA Nephropathy Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze IgA Nephropathy Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IgA Nephropathy Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of IgA Nephropathy Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IgA Nephropathy Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the IgA Nephropathy Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global IgA Nephropathy Drugs industry.

Chapter 3: Detailed analysis of IgA Nephropathy Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of IgA Nephropathy Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of IgA Nephropathy Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. IgA Nephropathy Drugs Industry Trends Table 2. IgA Nephropathy Drugs Industry Drivers Table 3. IgA Nephropathy Drugs Industry Opportunities and Challenges Table 4. IgA Nephropathy Drugs Industry Restraints Table 5. Global IgA Nephropathy Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global IgA Nephropathy Drugs Revenue Share by Company (2021-2026) Table 7. Global IgA Nephropathy Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global IgA Nephropathy Drugs Sales Volume Share by Company (2021-2026) Table 9. Global IgA Nephropathy Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global IgA Nephropathy Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global IgA Nephropathy Drugs Key Company Manufacturing Base & Headquarters Table 12. Global IgA Nephropathy Drugs Company, Product Type & Application Table 13. Global IgA Nephropathy Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global IgA Nephropathy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Phase I Table 18. Significant Companies of Phase II Table 19. Significant Companies of Phase III Table 20. Global IgA Nephropathy Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global IgA Nephropathy Drugs Sales Volume by Type (2021-2026) & (K Units) Table 22. Global IgA Nephropathy Drugs Sales Volume by Type (2027-2032) & (K Units) Table 23. Global IgA Nephropathy Drugs Sales Volume Share by Type (2021-2026) Table 24. Global IgA Nephropathy Drugs Sales Volume Share by Type (2027-2032) Table 25. Global IgA Nephropathy Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global IgA Nephropathy Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global IgA Nephropathy Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global IgA Nephropathy Drugs Sales Value Share by Type (2021-2026) Table 29. Global IgA Nephropathy Drugs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Clinical Treatment Table 31. Significant Companies of Drug Experiment Table 32. Global IgA Nephropathy Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global IgA Nephropathy Drugs Sales Volume by Application (2021-2026) & (K Units) Table 34. Global IgA Nephropathy Drugs Sales Volume by Application (2027-2032) & (K Units) Table 35. Global IgA Nephropathy Drugs Sales Volume Share by Application (2021-2026) Table 36. Global IgA Nephropathy Drugs Sales Volume Share by Application (2027-2032) Table 37. Global IgA Nephropathy Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global IgA Nephropathy Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global IgA Nephropathy Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global IgA Nephropathy Drugs Sales Value Share by Application (2021-2026) Table 41. Global IgA Nephropathy Drugs Sales Value Share by Application (2027-2032) Table 42. Global IgA Nephropathy Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global IgA Nephropathy Drugs Sales by Region (2021-2026) & (K Units) Table 44. Global IgA Nephropathy Drugs Sales Market Share by Region (2021-2026) Table 45. Global IgA Nephropathy Drugs Sales by Region (2027-2032) & (K Units) Table 46. Global IgA Nephropathy Drugs Sales Market Share by Region (2027-2032) Table 47. Global IgA Nephropathy Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global IgA Nephropathy Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global IgA Nephropathy Drugs Sales Value Share by Region (2021-2026) Table 50. Global IgA Nephropathy Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global IgA Nephropathy Drugs Sales Value Share by Region (2027-2032) Table 52. Global IgA Nephropathy Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global IgA Nephropathy Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global IgA Nephropathy Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global IgA Nephropathy Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global IgA Nephropathy Drugs Sales by Country (2021-2026) & (K Units) Table 57. Global IgA Nephropathy Drugs Sales Market Share by Country (2021-2026) Table 58. Global IgA Nephropathy Drugs Sales by Country (2027-2032) & (K Units) Table 59. Global IgA Nephropathy Drugs Sales Market Share by Country (2027-2032) Table 60. Global IgA Nephropathy Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global IgA Nephropathy Drugs Sales Value Market Share by Country (2021-2026) Table 62. Global IgA Nephropathy Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global IgA Nephropathy Drugs Sales Value Market Share by Country (2027-2032) Table 64. Calliditas Therapeutics Company Information Table 65. Calliditas Therapeutics Business Overview Table 66. Calliditas Therapeutics IgA Nephropathy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Calliditas Therapeutics IgA Nephropathy Drugs Product Portfolio Table 68. Calliditas Therapeutics Recent Development Table 69. Chinook Therapeutics Company Information Table 70. Chinook Therapeutics Business Overview Table 71. Chinook Therapeutics IgA Nephropathy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Chinook Therapeutics IgA Nephropathy Drugs Product Portfolio Table 73. Chinook Therapeutics Recent Development Table 74. Omeros Corporation Company Information Table 75. Omeros Corporation Business Overview Table 76. Omeros Corporation IgA Nephropathy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Omeros Corporation IgA Nephropathy Drugs Product Portfolio Table 78. Omeros Corporation Recent Development Table 79. Travere Therapeutics Company Information Table 80. Travere Therapeutics Business Overview Table 81. Travere Therapeutics IgA Nephropathy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Travere Therapeutics IgA Nephropathy Drugs Product Portfolio Table 83. Travere Therapeutics Recent Development Table 84. Vera Therapeutics Company Information Table 85. Vera Therapeutics Business Overview Table 86. Vera Therapeutics IgA Nephropathy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Vera Therapeutics IgA Nephropathy Drugs Product Portfolio Table 88. Vera Therapeutics Recent Development Table 89. Otsuka Pharmaceutical Company Information Table 90. Otsuka Pharmaceutical Business Overview Table 91. Otsuka Pharmaceutical IgA Nephropathy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Otsuka Pharmaceutical IgA Nephropathy Drugs Product Portfolio Table 93. Otsuka Pharmaceutical Recent Development Table 94. Novartis International Company Information Table 95. Novartis International Business Overview Table 96. Novartis International IgA Nephropathy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Novartis International IgA Nephropathy Drugs Product Portfolio Table 98. Novartis International Recent Development Table 99. Key Raw Materials Table 100. Raw Materials Key Suppliers Table 101. IgA Nephropathy Drugs Distributors List Table 102. IgA Nephropathy Drugs Customers List Table 103. Research Programs/Design for This Report Table 104. Authors List of This Report Table 105. Secondary Sources Table 106. Primary Sources List of Figures Figure 1. IgA Nephropathy Drugs Product Image Figure 2. Global IgA Nephropathy Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global IgA Nephropathy Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global IgA Nephropathy Drugs Sales (2021-2032) & (K Units) Figure 5. Global IgA Nephropathy Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global IgA Nephropathy Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Phase I Image Figure 10. Phase II Image Figure 11. Phase III Image Figure 12. Global IgA Nephropathy Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global IgA Nephropathy Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global IgA Nephropathy Drugs Sales Volume Share by Type (2021-2032) Figure 15. Global IgA Nephropathy Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global IgA Nephropathy Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global IgA Nephropathy Drugs Sales Value Share by Type (2021-2032) Figure 18. Clinical Treatment Image Figure 19. Drug Experiment Image Figure 20. Global IgA Nephropathy Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global IgA Nephropathy Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global IgA Nephropathy Drugs Sales Volume Share by Application (2021-2032) Figure 23. Global IgA Nephropathy Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global IgA Nephropathy Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global IgA Nephropathy Drugs Sales Value Share by Application (2021-2032) Figure 26. Global IgA Nephropathy Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global IgA Nephropathy Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global IgA Nephropathy Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global IgA Nephropathy Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America IgA Nephropathy Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. North America IgA Nephropathy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe IgA Nephropathy Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Europe IgA Nephropathy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific IgA Nephropathy Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific IgA Nephropathy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America IgA Nephropathy Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. South America IgA Nephropathy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa IgA Nephropathy Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa IgA Nephropathy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. IgA Nephropathy Drugs Value Chain Figure 125. Manufacturing Cost Structure Figure 126. IgA Nephropathy Drugs Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Phase I
  • Phase II
  • Phase III
Applications
  • Clinical Treatment
  • Drug Experiment
Companies covered
  • Calliditas Therapeutics
  • Chinook Therapeutics
  • Omeros Corporation
  • Travere Therapeutics
  • Vera Therapeutics
  • Otsuka Pharmaceutical
  • Novartis International

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global IgA Nephropathy Drugs Sales Value (2021-2032)
  4. 1.2.2 Global IgA Nephropathy Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global IgA Nephropathy Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 IgA Nephropathy Drugs Market Dynamics
  1. 2.1 IgA Nephropathy Drugs Industry Trends
  2. 2.2 IgA Nephropathy Drugs Industry Drivers
  3. 2.3 IgA Nephropathy Drugs Industry Opportunities and Challenges
  4. 2.4 IgA Nephropathy Drugs Industry Restraints
3 IgA Nephropathy Drugs Market by Company
  1. 3.1 Global IgA Nephropathy Drugs Company Revenue Ranking in 2025
  2. 3.2 Global IgA Nephropathy Drugs Revenue by Company (2021-2026)
  3. 3.3 Global IgA Nephropathy Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global IgA Nephropathy Drugs Average Price by Company (2021-2026)
  5. 3.5 Global IgA Nephropathy Drugs Company Ranking (2024-2026)
  6. 3.6 Global IgA Nephropathy Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global IgA Nephropathy Drugs Company Product Type and Application
  8. 3.8 Global IgA Nephropathy Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global IgA Nephropathy Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 IgA Nephropathy Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 IgA Nephropathy Drugs Market by Type
  1. 4.1 IgA Nephropathy Drugs Type Introduction
  2. 4.1.1 Phase I
  3. 4.1.2 Phase II
  4. 4.1.3 Phase III
  5. 4.2 Global IgA Nephropathy Drugs Sales Volume by Type
  6. 4.2.1 Global IgA Nephropathy Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global IgA Nephropathy Drugs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global IgA Nephropathy Drugs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global IgA Nephropathy Drugs Sales Value by Type
  10. 4.3.1 Global IgA Nephropathy Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global IgA Nephropathy Drugs Sales Value by Type (2021-2032)
  12. 4.3.3 Global IgA Nephropathy Drugs Sales Value Share by Type (2021-2032)
5 IgA Nephropathy Drugs Market by Application
  1. 5.1 IgA Nephropathy Drugs Application Introduction
  2. 5.1.1 Clinical Treatment
  3. 5.1.2 Drug Experiment
  4. 5.2 Global IgA Nephropathy Drugs Sales Volume by Application
  5. 5.2.1 Global IgA Nephropathy Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global IgA Nephropathy Drugs Sales Volume by Application (2021-2032)
  7. 5.2.3 Global IgA Nephropathy Drugs Sales Volume Share by Application (2021-2032)
  8. 5.3 Global IgA Nephropathy Drugs Sales Value by Application
  9. 5.3.1 Global IgA Nephropathy Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global IgA Nephropathy Drugs Sales Value by Application (2021-2032)
  11. 5.3.3 Global IgA Nephropathy Drugs Sales Value Share by Application (2021-2032)
6 IgA Nephropathy Drugs Regional Sales and Value Analysis
  1. 6.1 Global IgA Nephropathy Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global IgA Nephropathy Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global IgA Nephropathy Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global IgA Nephropathy Drugs Sales by Region (2027-2032)
  5. 6.3 Global IgA Nephropathy Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global IgA Nephropathy Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global IgA Nephropathy Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global IgA Nephropathy Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global IgA Nephropathy Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America IgA Nephropathy Drugs Sales Value (2021-2032)
  12. 6.6.2 North America IgA Nephropathy Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe IgA Nephropathy Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe IgA Nephropathy Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific IgA Nephropathy Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific IgA Nephropathy Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America IgA Nephropathy Drugs Sales Value (2021-2032)
  21. 6.9.2 South America IgA Nephropathy Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa IgA Nephropathy Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa IgA Nephropathy Drugs Sales Value Share by Country, 2025 VS 2032
7 IgA Nephropathy Drugs Country-level Sales and Value Analysis
  1. 7.1 Global IgA Nephropathy Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global IgA Nephropathy Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global IgA Nephropathy Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global IgA Nephropathy Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global IgA Nephropathy Drugs Sales by Country (2027-2032)
  6. 7.4 Global IgA Nephropathy Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global IgA Nephropathy Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global IgA Nephropathy Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt IgA Nephropathy Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt IgA Nephropathy Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt IgA Nephropathy Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Calliditas Therapeutics
  2. 8.1.1 Calliditas Therapeutics Company Information
  3. 8.1.2 Calliditas Therapeutics Business Overview
  4. 8.1.3 Calliditas Therapeutics IgA Nephropathy Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Calliditas Therapeutics IgA Nephropathy Drugs Product Portfolio
  6. 8.1.5 Calliditas Therapeutics Recent Developments
  7. 8.2 Chinook Therapeutics
  8. 8.2.1 Chinook Therapeutics Company Information
  9. 8.2.2 Chinook Therapeutics Business Overview
  10. 8.2.3 Chinook Therapeutics IgA Nephropathy Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Chinook Therapeutics IgA Nephropathy Drugs Product Portfolio
  12. 8.2.5 Chinook Therapeutics Recent Developments
  13. 8.3 Omeros Corporation
  14. 8.3.1 Omeros Corporation Company Information
  15. 8.3.2 Omeros Corporation Business Overview
  16. 8.3.3 Omeros Corporation IgA Nephropathy Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Omeros Corporation IgA Nephropathy Drugs Product Portfolio
  18. 8.3.5 Omeros Corporation Recent Developments
  19. 8.4 Travere Therapeutics
  20. 8.4.1 Travere Therapeutics Company Information
  21. 8.4.2 Travere Therapeutics Business Overview
  22. 8.4.3 Travere Therapeutics IgA Nephropathy Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Travere Therapeutics IgA Nephropathy Drugs Product Portfolio
  24. 8.4.5 Travere Therapeutics Recent Developments
  25. 8.5 Vera Therapeutics
  26. 8.5.1 Vera Therapeutics Company Information
  27. 8.5.2 Vera Therapeutics Business Overview
  28. 8.5.3 Vera Therapeutics IgA Nephropathy Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Vera Therapeutics IgA Nephropathy Drugs Product Portfolio
  30. 8.5.5 Vera Therapeutics Recent Developments
  31. 8.6 Otsuka Pharmaceutical
  32. 8.6.1 Otsuka Pharmaceutical Company Information
  33. 8.6.2 Otsuka Pharmaceutical Business Overview
  34. 8.6.3 Otsuka Pharmaceutical IgA Nephropathy Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Otsuka Pharmaceutical IgA Nephropathy Drugs Product Portfolio
  36. 8.6.5 Otsuka Pharmaceutical Recent Developments
  37. 8.7 Novartis International
  38. 8.7.1 Novartis International Company Information
  39. 8.7.2 Novartis International Business Overview
  40. 8.7.3 Novartis International IgA Nephropathy Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Novartis International IgA Nephropathy Drugs Product Portfolio
  42. 8.7.5 Novartis International Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 IgA Nephropathy Drugs Value Chain Analysis
  2. 9.1.1 IgA Nephropathy Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 IgA Nephropathy Drugs Sales Mode & Process
  6. 9.2 IgA Nephropathy Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 IgA Nephropathy Drugs Distributors
  9. 9.2.3 IgA Nephropathy Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst